feed,title,long_url,short_url
SeekingAlpha,RAPT Therapeutics plunges 40% as it ends phase 2 study of lead asset zelnecirnon,https://seekingalpha.com/news/4103923,
SeekingAlpha,Top 10 Holdings In My 15% Yielding Income Compounder Portfolio,https://seekingalpha.com/article/4691344,
